Spero Therapeutics stockholders approve 3M share increase to 2017 Stock Incentive Plan at annual meeting

Spero Therapeutics, Inc.

Stockholders approved amendment to 2017 Plan increasing authorized shares by 3,000,000.
Reelected Class II directors Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu to 2028 meeting.
Ratified PricewaterhouseCoopers as independent auditor for fiscal year 2025.
Advisory vote on executive compensation passed with 25.2M for, 0.6M against.
Quorum of 40,015,633 shares (71.57%) present at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.